Devices and processes for delivering therapeutic fluids

By designing a therapeutic agent delivery system for housing, needle and pressure generation actuator, the problem of high viscosity drug delivery is solved, patient comfort and flexibility of delivery system are improved, and high-concentration of protein therapeutic agents are achieved.

CN113164681BActive Publication Date: 2024-12-06ELI LILLY & CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980084719.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-12-19
Filing Date
2019-12-12
Publication Date
2024-12-06
Estimated Expiration
2039-12-12

AI Technical Summary

Technical Problem

Existing methods for delivery of protein therapeutic agents have difficulties, including the difficulty of high viscosity drugs delivered through conventional spring-driven auto-injectors, resulting in reduced design flexibility, impact on patient comfort and compliance, and the inability to finely regulate delivery pressure.

Method used

A therapeutic agent delivery system is designed, including a housing, needle and a pressure generation actuator, allowing the needle to expand and contract, using the pressure generation actuator to transfer the therapeutic agent from The channel is delivered to the needle and the delivery process is adjusted by the movement of the sleeve, enabling smaller needle diameter and faster delivery time.

Benefits of technology

The possibility of delivering high concentrations of high viscosity drugs within a reasonable time is achieved, improving patient comfort and compliance, enhancing the design flexibility of delivery systems, and allowing fine adjustment of delivery pressure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113164681B_ABST
    Figure CN113164681B_ABST
Patent Text Reader

Abstract

A therapeutic agent delivery system includes a housing. A therapeutic agent delivery assembly is carried by the housing. The therapeutic agent delivery assembly includes a chamber having a channel. A therapeutic agent is carried in the channel, and a needle is in communication with the channel. The therapeutic agent delivery assembly may translate relative to the housing from a stowed configuration to an expanded configuration. Actuation of a user input may cause the therapeutic agent delivery assembly to translate from the stowed configuration to the expanded configuration. An input member constraint may be rotatable relative to the housing from a first rotational configuration to a second rotational configuration. In the first rotational configuration, the input member constraint may prevent actuation of the user input member; and in the second rotational configuration, the input member constraint may allow actuation of the user input member.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 62 / 781,662 (Attorney Docket No. P21837), filed on December 19, 2018, the entire disclosure of which is hereby expressly incorporated herein by reference. Technical Field

[0003] The present disclosure relates to processes and devices for parenteral delivery of therapeutic agents. More particularly, the present disclosure relates to processes and devices for parenteral delivery of high viscosity therapeutic fluids (eg, protein therapeutics). Background Art

[0004] Protein therapeutics are an emerging class of drug therapies that provide treatment for a variety of diseases, such as autoimmune diseases, cardiovascular diseases, diabetes, and cancer. A common delivery method for some protein therapeutics, such as monoclonal antibodies, is by intravenous infusion, where large amounts of dilute solutions are delivered over time. Intravenous infusions typically require the supervision of a doctor or nurse and are performed in a clinical setting. This can be inconvenient for patients, and efforts are therefore being made to allow protein therapeutics to be delivered at home. It is desirable that protein therapeutic preparations can be administered using a syringe for subcutaneous delivery without the need for intravenous administration. Subcutaneous injections are typically administered by non-professionals, such as when insulin is administered by diabetic patients.

[0005] The transfer of therapeutic protein formulations from intravenous delivery to injection devices (such as syringes and injection pens) requires addressing the challenges associated with delivering high concentrations of high molecular weight molecules in an easy, reliable and minimally painful manner for the patient. In this regard, although IV bags typically have a volume of 1 liter, the standard volume of syringes ranges from 0.3 ml to 25 ml. Thus, depending on the drug, in order to deliver the same amount of therapeutic protein, the concentration may have to be increased by 40 times or more. In addition, for the purpose of patient comfort and compliance, injection therapy is developing towards smaller needle diameters and faster delivery times.

[0006] The delivery of protein therapeutics is challenging, also because of the high viscosity associated with such therapeutic formulations, and the large force required to push such formulations through parenteral devices. Formulations with an absolute viscosity above 40-60 centipoise (cP) can be difficult to deliver by conventional spring-driven automatic injectors for a variety of reasons. Structurally, the volume of the spring used for the amount of pressure delivered is relatively large and fixed to a specific shape, which reduces the design flexibility of the delivery device. Next, the automatic injector is usually made of plastic parts. However, a large amount of energy must be stored in the spring to reliably deliver high-viscosity fluids. If not properly designed, this stored energy can cause damage to the plastic parts due to creep, which is the tendency of plastic parts to permanently deform under stress. The automatic injector typically operates by using a spring to push the internal member containing the needle toward the outer edge of the syringe housing. The sound associated with the operation of the spring-based automatic injector can cause patient anxiety, thereby potentially reducing future compliance. The pressure curve generated by such a spring-driven automatic injector relative to time cannot be easily modified, which prevents the user from fine-tuning the pressure to meet their delivery needs.

[0007] It would be desirable to provide processes and devices by which therapeutic fluids, particularly high viscosity fluids, can be self-administered in a reasonable amount of time and with limited injection space. These processes and devices can be used to deliver high concentration proteins, high viscosity drug formulations, or other therapeutic fluids. Summary of the invention

[0008] According to an embodiment of the present disclosure, a therapeutic agent delivery system includes a housing having a distal portion. A therapeutic agent delivery assembly is carried by the housing. The therapeutic agent delivery assembly includes a chamber having a channel. The therapeutic agent is carried in the channel, and the needle is in communication with the channel. The therapeutic agent delivery assembly can be translated relative to the housing from a stowed configuration to an expanded configuration, in which the needle at least partially extends distally from the distal portion of the housing. The user input is configured to be actuated by a user. Actuation of the user input causes the therapeutic agent delivery assembly to translate from the stowed configuration to the expanded configuration. The input member constraint can be rotated relative to the housing from a first rotational configuration to a second rotational configuration. In the first rotational configuration, the input member constraint prevents actuation of the user input member, and in the second rotational configuration, the input member constraint allows actuation of the user input member. The sleeve can be translated relative to the housing from an exposed configuration to a retracted configuration. In the exposed configuration, the sleeve partially extends distally from the distal end of the housing. When translated from the exposed configuration to the retracted configuration, the sleeve causes the input member constraint to rotate from the first rotational configuration to the second rotational configuration.

[0009] According to another embodiment of the present disclosure, a therapeutic agent delivery system includes a housing having a distal portion. A therapeutic agent delivery assembly is carried by the housing. The therapeutic agent delivery assembly includes a chamber, the chamber including a channel. The therapeutic agent is carried in the channel. The needle is in communication with the channel. A pressure generating actuator is in communication with the channel, and actuation of the pressure generating actuator delivers the therapeutic agent from the channel to the needle and causes the therapeutic agent to be discharged from the needle. The therapeutic agent delivery assembly is translatable relative to the housing from a stowed configuration to an expanded configuration. In the expanded configuration, the needle extends distally at least partially from the distal portion of the housing. The user input is configured to be actuated by a user. Actuation of the user input actuates the pressure generating actuator. The input member constraint is rotatable relative to the housing from a first rotational configuration to a second rotational configuration. In the first rotational configuration, the input member constraint prevents actuation of the user input, and in the second rotational configuration, the input member constraint allows actuation of the user input. The sleeve is translatable relative to the housing from an exposed configuration to a retracted configuration. The sleeve partially extends distally from the distal end portion of the housing in the exposed configuration, and the sleeve rotates the input member constraint from the first rotational configuration to the second rotational configuration when translated from the exposed configuration to the retracted configuration.

[0010] According to yet another embodiment of the present disclosure, a therapeutic agent delivery system includes a housing having a distal portion. A therapeutic agent delivery assembly is carried by the housing. The therapeutic agent delivery assembly includes a chamber having a channel. A therapeutic agent is carried in the channel. A needle is in communication with the channel. A pressure generating actuator is in communication with the channel. Actuation of the pressure generating actuator delivers the therapeutic agent from the channel to the needle and causes the therapeutic agent to be expelled from the needle. The therapeutic agent delivery assembly is translatable relative to the housing from a stowed configuration to an expanded configuration. In the expanded configuration, the needle at least partially extends distally from the distal portion of the housing. The user input is configured to be actuated by a user. Actuation of the user input translates the therapeutic agent delivery assembly from the stowed configuration to the expanded configuration and actuates the pressure generating actuator. The input member constraint is movable relative to the housing from a first configuration to a second configuration. In the first configuration, the input member constraint prevents actuation of the user input member, and in the second configuration, the input member constraint allows actuation of the user input member. The sleeve is translatable relative to the housing from an exposed configuration to a retracted configuration. In the exposed configuration, the sleeve partially extends distally from the distal end portion of the housing, and when translated from the exposed configuration to the retracted configuration, the sleeve moves the input member constraint from the first configuration to the second configuration.

[0011] According to yet another embodiment of the present disclosure, a therapeutic agent delivery system includes a housing having a proximal portion and a distal portion. A user input is coupled to the proximal portion of the housing and is configured to be actuated by a user. A sleeve is coupled to the distal portion of the housing. A therapeutic agent delivery assembly is carried by the housing. The therapeutic agent delivery assembly includes: a chamber including a channel; a therapeutic agent carried in the channel; a needle communicating with the channel; and a pressure generating actuator communicating with the channel. The therapeutic agent delivery system has a locked configuration in which the sleeve at least partially extends distally from the distal portion of the housing; an unlocked configuration in which the sleeve is forced into the distal portion of the housing; an expanded configuration in which the needle at least partially extends distally from the distal portion of the housing; and an actuated configuration in which pressurized fluid from the pressure generating actuator delivers the therapeutic agent from the channel to the needle and discharges the therapeutic agent from the needle. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] The above and other features and advantages of the present disclosure and their implementation will become more apparent and better understood by referring to the following description of the embodiments of the present invention in conjunction with the accompanying drawings, in which:

[0013] Figure 1 is a top perspective view of a therapeutic agent delivery system according to an embodiment of the present disclosure.

[0014] Figure 2 yes Figure 1 Exploded view of a therapeutic agent delivery system.

[0015] Figure 3 is along Figure 1 Line 3-3 is a longitudinal cross-sectional view of the therapeutic agent delivery system.

[0016] Figure 4 yes Figure 1 A top perspective view of a distal housing portion of a housing of a therapeutic agent delivery system.

[0017] Figure 5 is along Figure 4 A longitudinal cross-sectional view of the distal housing portion along line 5-5.

[0018] Figure 6 is along Figure 4 A longitudinal cross-sectional view of the distal housing portion along line 6-6.

[0019] Figure 7 yes Figure 1 A top perspective view of a proximal housing portion of a housing of a therapeutic agent delivery system.

[0020] Figure 8 is along Figure 7 A longitudinal cross-sectional view of the proximal housing portion along line 8-8.

[0021] Fig. 9 is along Figure 7 A longitudinal cross-sectional view of the proximal housing portion along line 9-9.

[0022] Fig.10 yes Figure 1 A top perspective view of a sleeve of a therapeutic agent delivery system.

[0023] Fig.11 is along Fig.10 A longitudinal cross-sectional view of the sleeve along line 11-11.

[0024] Fig.12 is along Fig.10 A longitudinal cross-sectional view of the sleeve along line 12-12.

[0025] Fig.13 yes Figure 1 A top perspective view of a user input member support of a therapeutic agent delivery system.

[0026] Fig.14 yes Figure 1 A top perspective view of a user input component of a therapeutic agent delivery system.

[0027] Fig.15 yes Figure 1 A top perspective view of an input member constraint of a therapeutic agent delivery system.

[0028] Fig.16 yes Figure 1 A bottom perspective view of a pressure generating actuator of a therapeutic agent delivery assembly of a therapeutic agent delivery system.

[0029] Fig.17 yes Fig.16 A top perspective view of a pressure generating actuator.

[0030] Fig.18 yes Fig.16 Exploded perspective view of a pressure generating actuator.

[0031] Fig.19 is along Fig.16 A longitudinal cross-sectional view of the pressure generating actuator taken along line 19-19.

[0032] Fig. 20 yes Figure 1 A side view of a syringe assembly of a therapeutic agent delivery assembly of a therapeutic agent delivery system.

[0033] Fig.21 is along Fig. 20 A longitudinal cross-sectional view of the syringe assembly taken along line 21-21.

[0034] Fig. 22 yes Figure 1 A top perspective view of the electronic components of a therapeutic agent delivery system.

[0035] Fig.23 yes Fig. 22 Schematic representation of the electronic components.

[0036] Fig.24 is from Figure 1 A top perspective view of a distal portion of a therapeutic agent delivery system with the end cap and needle cover removed.

[0037] Fig.25 In the first configuration Figure 1 A side perspective view of a therapeutic agent delivery system; the housing is shown with hidden lines to illustrate internal components.

[0038] Fig.26 is Fig.25 Detailed top perspective view of the therapeutic agent delivery system within line 26-26 and in a first configuration.

[0039] Fig. 27 In the first configuration Figure 1 A longitudinal partial cross-sectional view of a therapeutic agent delivery system; the housing is shown with hidden lines to illustrate internal components.

[0040] Fig.28 is Fig. 27 Detailed side perspective view of the therapeutic agent delivery system within line 28-28 and in a first configuration.

[0041] Fig.29 In the second configuration Figure 1 A side perspective view of a therapeutic agent delivery system; the housing is shown with hidden lines to illustrate internal components.

[0042] Fig.30 is Fig.29 Detailed top perspective view of the therapeutic agent delivery system within line 30-30 and in a second configuration.

[0043] Fig.31 In the second configuration Figure 1 A longitudinal partial cross-sectional view of a therapeutic agent delivery system; the housing is shown with hidden lines to illustrate internal components.

[0044] Fig.32 is Fig.31 Detailed side perspective view of the therapeutic agent delivery system within line 32-32 and in the second configuration.

[0045] Fig.33 When a user input is actuated Figure 1 Detailed top perspective view of a therapeutic agent delivery system; the housing is shown with hidden lines to illustrate internal components.

[0046] Fig.34is the edge when actuating the user input Fig.33 A cross-sectional view of the therapeutic agent delivery system along line 34-34.

[0047] Fig.35 When the deployment spring expands and moves the therapeutic agent delivery assembly distally relative to the housing Figure 1 Detailed top perspective view of a therapeutic agent delivery system; the housing is shown with hidden lines to illustrate internal components.

[0048] Fig.36 is when the therapeutic agent delivery assembly moves to the deployed configuration Figure 1 Longitudinal partial cross-sectional view of a therapeutic agent delivery system.

[0049] Fig.37 is a longitudinal cross-sectional view of a shuttle of a pressure generating actuator that rotates relative to first and second mixing chambers of the pressure generating actuator and thereby actuates the actuator.

[0050] Fig.38 is a longitudinal cross-sectional view of a shuttle and a mixing piston of a pressure generating actuator in an actuated configuration.

[0051] Fig.39 When the syringe piston moves in the syringe channel to expel the therapeutic agent from the needle Figure 1 Longitudinal partial cross-sectional view of a therapeutic agent delivery system; the syringe chamber is shown in hidden lines to illustrate the syringe piston.

[0052] Fig.40 When the syringe channel and needle move to the withdrawn configuration Figure 1 Longitudinal partial cross-sectional view of a therapeutic agent delivery system; the syringe chamber is shown in hidden lines to illustrate the syringe piston.

[0053] Fig.41 When the protrusion of the housing and the sleeve engage with each other Figure 1 Longitudinal cross-sectional view of a therapeutic agent delivery system; the syringe chamber is shown with hidden lines.

[0054] Fig.42 is a longitudinal cross-sectional view of a therapeutic agent delivery system according to another embodiment of the present disclosure.

[0055] Fig.43 is Fig.42 Detailed longitudinal cross-sectional view of the therapeutic agent delivery system within line 43-43.

[0056] Fig.44 is when the mixing piston of the pressure generating actuator moves to the actuated configuration Fig.42 Detailed longitudinal cross-sectional view of the therapeutic agent delivery system within line 43-43.

[0057] Fig.45 When the intermediate piston and syringe assembly are translated Fig.42 Longitudinal cross-sectional view of a therapeutic agent delivery system.

[0058] Fig.46 is Fig.45 Detailed longitudinal cross-sectional view of the therapeutic agent delivery system within line 46-46.

[0059] Fig.47 is when the syringe piston translates and the therapeutic agent is delivered Fig.42 Longitudinal partial cross-sectional view of a therapeutic agent delivery system.

[0060] Corresponding reference numerals indicate corresponding parts throughout the several views of the drawings.The exemplifications set out herein illustrate exemplary embodiments of the invention, and such exemplifications should not be construed as limiting the scope of the invention in any way. DETAILED DESCRIPTION

[0061] The present disclosure relates to systems, devices, and processes for parenteral delivery of therapeutic agents, such as high viscosity therapeutic fluids.

[0062] 1. Drugs / therapeutic agents

[0063] Systems and devices according to the present disclosure can carry and facilitate the delivery of drugs to subjects. The term "drug" refers to one or more therapeutic agents, including but not limited to insulin, insulin analogs (such as insulin lispro or insulin glargine), insulin derivatives, GLP-1 receptor agonists (such as dulaglutide or liraglutide), glucagon, glucagon analogs, glucagon derivatives, gastric inhibitory polypeptide (GIP), GIP analogs, GIP derivatives, oxyntomodulin analogs, oxyntomodulin derivatives, therapeutic antibodies, and any therapeutic agent that can be delivered by a device according to the present disclosure. The drug can be formulated with one or more excipients. The device according to the present disclosure is operated by a patient, a caregiver, or a healthcare professional in a manner generally as described herein to deliver the drug to a subject.

[0064] In certain embodiments, the therapeutic agent is a protein, such as a monoclonal antibody or some other therapeutically useful protein. In certain embodiments, the protein may have a concentration in the fluid from about 75 mg / mL to about 500 mg / mL. In certain embodiments, the protein may have a concentration of about 150 mg / mL, 200 mg / mL, 250 mg / mL or more. The drug may further comprise a solvent or non-solvent, such as water, a perfluoroalkane solvent, safflower oil, or benzyl benzoate.

[0065] The drug may be a fluid, more specifically a high viscosity fluid, and may have an absolute viscosity from about 5 cP to about 1000 cP. In certain embodiments, the high viscosity fluid has an absolute viscosity of at least about 10 cP, 20 cP, 30 cP, 40 cP, 50 cP, 60 cP or more.

[0066] 2. Therapeutic agent delivery systems

[0067] Figure 1-3 A therapeutic agent delivery system 10 is illustrated in accordance with an embodiment of the present disclosure. Illustratively, the therapeutic agent delivery system 10 generally comprises the form factor of an autoinjector pen, although other forms may alternatively be used. Generally, the therapeutic agent delivery system 10 comprises an elongated housing 12 along a longitudinal axis 14. The housing 12 carries a therapeutic agent delivery assembly 16. The therapeutic agent delivery assembly 16 comprises a therapeutic agent and a needle 18, and the therapeutic agent delivery assembly 16 translates relative to the housing 12 from a stowed configuration (e.g., in a closed position). Figure 1-3 The therapeutic agent delivery system 10 is illustratively shown in Figure 1, wherein the needle 18 is fully disposed within the housing 12) to a deployed configuration (shown elsewhere—e.g., a configuration in which the needle 18 is at least partially exposed from the housing 12 and is configured to engage with a subject and deliver a therapeutic agent to the subject). The therapeutic agent delivery assembly 16 also translates relative to the housing 12 from the deployed configuration to a withdrawn configuration (shown elsewhere—e.g., a configuration in which the needle 18 is fully disposed within the therapeutic agent delivery system 10). The proximal portion 20 of the therapeutic agent delivery system 10 includes a user input 22 (illustratively, a depressible button) that is actuated to actuate the therapeutic agent delivery assembly 16 (i.e., to move the needle 18 from the stowed configuration to the deployed configuration and deliver the therapeutic agent to the user). The therapeutic agent delivery system 10 generally prevents the user input 22 from being actuated (in other words, the user input 22 is generally "locked"). The therapeutic agent delivery system 10 also includes a sleeve 24 that is generally exposed at a distal portion 26 of the system 10. Sleeve 24 is pressed against a surface (e.g., the subject's skin) to allow user input 22 to be actuated (in other words, to "unlock" user input 22). The therapeutic agent delivery system 10 can then be actuated by pressing user input 22. After disengaging the therapeutic agent delivery system 10 from the surface, needle 18 translates to the withdrawn configuration and is prevented from translating to the deployed configuration (in other words, the system 10 "locks"). These aspects, features, and components of the therapeutic agent delivery system 10 are described in further detail below.

[0068] Figure 4-6The distal housing portion 28 of the housing 12 is illustrated. The distal housing portion 28 includes a body 30 having a generally cylindrical shape. The body 30 includes an inner passage 32 that carries other components of the therapeutic agent delivery system 10. Adjacent the inner passage 32, an inner surface 34 of the distal housing portion 28 carries a restriction feature that selectively engages the therapeutic agent delivery assembly 16, as described in further detail below. Illustratively, the restriction feature includes two radially inwardly extending protrusions 36. As shown in FIG. Figure 5 As shown in FIG. 1 , the projection 36 faces the distal portion 26 ( Figure 1 ) is tapered radially inward. In other embodiments, different arrangements of the distal housing portion 28 are possible. For example, the restriction feature may be a non-tapered protrusion.

[0069] Figure 7-9 A proximal housing portion 38 of the housing 12 is shown. The proximal housing portion 38 includes a body 40 having a generally cylindrical shape. The body 40 includes an inner channel 42 that carries other components of the therapeutic agent delivery system 10. Adjacent the inner channel 42, an inner surface 44 of the proximal housing portion 38 carries an actuation feature (illustratively, two helically extending ramps 46), as described in further detail below, which selectively engages the therapeutic agent delivery assembly 16 and facilitates its actuation. The inner surface 44 of the proximal housing portion 38 carries a translation feature (illustratively, four axially extending ridges 48) that facilitates translation of the sleeve 24 in the inner channel 42. The inner surface 44 also carries a biasing feature (illustratively, a radially inwardly extending flange 50), as described in further detail below, which engages a spring (shown elsewhere). The proximal housing portion 38 includes a coupling feature (illustratively, a plurality of snap-fit ​​connections 52) for coupling to the distal housing portion 28. In other embodiments, different arrangements of the proximal housing portion 38 are possible. For example, the proximal housing portion 38 can be integrally formed with the distal housing portion 28.

[0070] Figure 10-12 The sleeve 24 of the therapeutic agent delivery system 10 is illustrated. Illustratively, the sleeve 24 is formed of an electrically conductive material (e.g., metal) to facilitate (as described in further detail below) operative coupling of components of an electronic assembly (shown elsewhere) of the therapeutic agent delivery system 10. The sleeve 24 includes a distal sleeve portion 54 having a generally cylindrical shape. The distal sleeve portion 54 includes an inner passage 56 that carries components of the therapeutic agent delivery assembly 16. The distal sleeve portion 54 includes a restraining feature (illustratively, two radially outwardly extending protrusions 58) for selectively engaging a restraining feature (illustratively, two radially inwardly extending and inwardly deflectable protrusions 36) of the distal housing portion 28 and, as described in further detail below, selectively preventing translation of the sleeve 24 relative to the distal housing portion 28. As shown in FIG. Fig.11 As shown in FIG. 1 , the projection 58 is away from the distal portion 26 ( Figure 1 ) tapers radially outwardly. The distal sleeve portion 54 is coupled to two proximally and axially extending arms 60. The axially extending arms 60 carry translation features (illustratively, four axially extending ridges 62) that engage translation features (illustratively, four axially extending ridges 48) of the proximal housing portion 38 to facilitate translation of the sleeve 24 within the housing 12 and to prevent rotation thereof. The axially extending arms 60 also define a cam and slot mechanism with the therapeutic agent delivery assembly 16 that facilitates rotation of the therapeutic agent delivery assembly 16 relative to the housing 12 as the sleeve 24 translates relative to the housing 12. Illustratively, the axially extending arms 60 each include a slot 64 of the cam and slot mechanism, and the slots 64 translationally receive a cam (shown elsewhere) of the therapeutic agent delivery assembly 16. Illustratively, the slots 64 include a helically extending proximal slot portion 66 and an axially extending distal slot portion 68. In other embodiments, different arrangements of the sleeve 24 are possible. For example, the slot 64 of the axially extending arm 60 may have a different shape, or the axially extending arm 60 may include a cam instead of a slot.

[0071] Fig.13 A user input support 70 of the therapeutic agent delivery system 10 is illustrated. The user input support 70 is coupled to the proximal housing portion 38 opposite the distal housing portion 28. The user input support 70 includes a body 72, and the body 72 carries coupling features (illustratively, a plurality of snap connections 74) for coupling to the proximal housing portion 38. The body 72 includes an internal passage 76 in which the user input 22 is received. Adjacent the internal passage 76, an inner surface 78 of the user input support 70 carries a translation feature (illustratively, a plurality of axially extending ridges 80) that facilitates translation of the user input 22 relative to the user input support 70. In other embodiments, different arrangements of the user input support 70 are possible.

[0072] Fig.14The user input 22 of the therapeutic agent delivery system 10 is illustrated. The user input 22 includes a translation feature (illustratively, a plurality of axially extending grooves 82) for engaging a translation feature (illustratively, a plurality of axially extending ridges 80) of the user input support 70 to facilitate translation of the user input 22 relative to the user input support 70 and the housing 12. Adjacent to the translation feature, the user input 22 includes an exposed portion 84 that a user presses to translate the user input 22 relative to the user input support 70 and the housing 12. The user input 22 also includes an actuation feature that facilitates actuation of the therapeutic agent delivery assembly 16. Illustratively, the actuation feature includes two arms 86 disposed opposite the exposed portion 84. Each of the arms 86 includes a constraining surface (illustratively, a circumferentially extending surface 88) and an actuation surface (illustratively, a helically extending surface 90). The interaction of the arms 86 with other components of the therapeutic agent delivery system 10 is described in further detail below. In other embodiments, different arrangements of user input 22 are possible.

[0073] Fig.15 An input member constraint 92 of the therapeutic agent delivery system 10 is illustrated. The input member constraint 92 includes an actuation feature that is configured to interact with an actuation feature of the user input 22. Illustratively, the actuation feature of the input member constraint 92 includes two partial flanges 94 and two openings 96 disposed between the partial flanges 94. Each of the partial flanges 94 includes a constraint surface (illustratively, a circumferentially extending surface 98) that, in some cases and as described in further detail below, engages one of the constraint surfaces 88 of the user input 22 to prevent translation of the user input 22 relative to the housing 12. Each of the partial flanges 94 also includes an actuation surface (illustratively, a radius 100 adjacent one of the openings 96) that, in some cases, engages one of the actuation surfaces 90 of the user input 22 to facilitate rotation of the input member constraint 92 relative to the housing 12 as the user input 22 translates relative to the housing 12. In contrast to the actuation features, the input constraint 92 includes a removable coupling feature (illustratively, a plurality of bosses 102 or radially outwardly extending L-shaped protrusions 102) that removably couple the input constraint 92 to the therapeutic agent delivery assembly 16. In other embodiments, different arrangements of the input constraint 92 are possible.

[0074] Figure 16-19The pressure generating actuator 104 of the therapeutic agent delivery assembly 16 is illustrated. Typically, the pressure generating actuator 104 is actuated by the user input 22 via the input constraint 92 to facilitate mixing of chemical reagents carried inside, which generates one or more pressurized fluids (e.g., one or more gases). Examples of suitable reagents and generated gases are provided below. As described in further detail below, the pressurized fluid is delivered to other components of the therapeutic agent delivery assembly 16 and facilitates their movement.

[0075] The pressure generating actuator 104 includes a first mixing chamber 106 and a second mixing chamber 108, which are illustratively formed integrally with each other. At the outlet end portion 110, the mixing chambers 106, 108 include an outlet coupling feature (illustratively, an external threaded surface 112) for coupling to another component of the therapeutic agent delivery assembly 16. The outlet end portion 110 also includes an actuator outlet 114 through which the pressurized fluid is discharged from the pressure generating actuator 104. The mixing chambers 106, 108 also define a cam and slot mechanism with the sleeve 24. Illustratively, the mixing chambers 106, 108 carry radially outwardly extending fingers or cams 116 of the cam and slot mechanism, and the cams 116 are translationally received in the slots 64 of the sleeve 24. In other embodiments, different arrangements are possible. For example, the mixing chambers 106, 108 may include slots instead of cams.

[0076] Internally, the mixing chambers 106, 108 carry an actuator spring 118, a mixing piston 120, and a rotatable shuttle 122 in an axially stacked arrangement. The rotatable shuttle 122 includes a recess 124, and the recess 124 carries a removable coupling feature (illustratively, a plurality of bosses 126 or radially outwardly extending L-shaped protrusions 126) that engages a removable coupling feature (illustratively, a plurality of bosses 102) of the input member constraint 92. The first mixing chamber 106 and the shuttle 122 form a helical coupling for movably coupling to each other. Illustratively, the shuttle 122 includes a helical extending ridge 128, and the first mixing chamber 106 includes a helical extending groove 130 that receives the ridge 128. The shuttle 122 includes an actuation feature (illustratively, two radially outwardly extending fingers 132) that, as described in further detail below, engages with and is driven by an actuation feature (illustratively, two helically extending ramps 46) of the proximal housing portion 38. Internally, the shuttle 122 includes a first restriction feature (illustratively, eight radially inwardly extending protrusions 134) that engages with the mixing piston 120. The shuttle 122 also illustratively includes a groove 136 disposed between adjacent protrusions 134. The mixing piston 120 includes a second restriction feature (illustratively, eight radially outwardly extending protrusions 138) that engages with the first restriction feature of the shuttle 122. Initially and as Fig.19, the first restriction feature engages with the second restriction feature (illustratively, the radially inwardly extending protrusion 134 of the shuttle 122 is angularly aligned and engaged with the radially outwardly extending protrusion 138 of the mixing piston 120) to maintain the mixing piston 120 in position between the first mixing chamber 106 and the second mixing chamber 108. Thus, the mixing piston 120 maintains separation of the reagents in the first mixing chamber 106 and the second mixing chamber 108. Initially, the actuator spring 118 is also compressed against the mixing piston 120 within the second mixing chamber 108. In a subsequent configuration, as described in further detail below, the shuttle 122 is rotated relative to the first and second mixing chambers 106, 108 to disengage the first restriction feature from the second restriction feature (illustratively, the radially inwardly extending protrusion 134 of the shuttle 122 is angularly misaligned or offset from the radially outwardly extending protrusion 138 of the mixing piston 120, and the groove 136 is angularly aligned with the radially outwardly extending protrusion 138 of the mixing piston 120). As a result, the actuator spring 118 expands and moves the mixing piston 120 into the shuttle 122 and the first mixing chamber 106, which allows the reagents in the first and second mixing chambers 106, 108 to mix. The mixing of the reagents generates one or more pressurized fluids (e.g., one or more gases), and the pressurized fluids are delivered to other components of the therapeutic agent delivery assembly 16. The reagents may be mixed only in the first mixing chamber 106 or in both mixing chambers 106, 108.

[0077] In some embodiments, the pressure generating actuator 104 has different structures. For example, suitable pressure generating actuators 104 include those described in the following documents: U.S. Patent No. 9,795,740, entitled "Chemical Engines and Methods for Their Use, Especially in the Injection of Highly Viscous Fluids"; PCT International Application No. PCT / US2018 / 017547, entitled "Processes and Devices for Delivery of Fluid by Chemical Reaction" and filed on February 9, 2018; and PCT International Application No. PCT / US2018 / 049048, entitled "System for Controlling Gas Generation with a Drug Delivery Device" and filed on August 31, 2018, the disclosures of which are expressly incorporated herein by reference in their entirety.

[0078] Any suitable chemical reagent or multiple chemical reagents can be used to generate one or more pressurized fluids in the pressure generating actuator 104 of the present disclosure. Examples of generated gases include carbon dioxide gas, nitrogen, oxygen, chlorine, etc. Desirably, the generated gas is inert and non-flammable. The amount of gas required to facilitate the movement of other components of the therapeutic agent delivery assembly 16 can affect the type, amount, and concentration of each reagent used in the pressure generating actuator 104. The reagents may be in dry form (e.g., powder form, tablet form, and / or low density lyophilized solid form) and / or in liquid form (e.g., solution, colloid, or stable or unstable suspension).

[0079] In an exemplary embodiment, a bicarbonate (which may be present in dry form) reacts with an acid (which may be present in liquid form) to produce carbon dioxide gas in the pressure generating actuator 104. Examples of suitable bicarbonates include sodium bicarbonate, potassium bicarbonate, and ammonium bicarbonate. Other ingredients may also be present with the bicarbonate, such as diatomaceous earth. Examples of suitable acids include acetic acid, citric acid, potassium bitartrate, disodium pyrophosphate, and monocalcium phosphate. In a specific example, the bicarbonate is potassium bicarbonate and the acid is an aqueous citric acid solution, which may react to produce carbon dioxide gas and a liquid mixture of water and dissolved potassium citrate.

[0080] In some embodiments, other reactions may be used. In one example, a metal carbonate (such as copper carbonate or calcium carbonate) is thermally decomposed to produce carbon dioxide gas and a corresponding metal oxide in the pressure generating actuator 104. In another example, 2,2'-azobisisobutyronitrile (AIBN) is heated to produce nitrogen gas in the pressure generating actuator 104. In yet another example, an enzyme (e.g., yeast) reacts with sugar to produce carbon dioxide gas in the pressure generating actuator 104. Some substances are easily sublimated, thereby changing from a solid to a gas. Such substances include, but are not limited to, naphthalene and iodine. In yet another example, hydrogen peroxide is decomposed with a catalyst such as an enzyme (e.g., catalase) or manganese dioxide to produce oxygen in the pressure generating actuator 104. In yet another example, silver chloride is decomposed by exposure to light to generate gas in the pressure generating actuator 104. Suitable reagents, chemicals, and reactions are further described in U.S. Pat. No. 9,795,740, PCT International Application No. PCT / US2018 / 017547, and PCT International Application No. PCT / US2018 / 049048, incorporated herein by reference.

[0081] Figure 20-21The syringe assembly 140 of the therapeutic agent delivery assembly 16 is illustrated. The syringe assembly 140 includes an inlet portion 142, and the inlet portion 142 includes an inlet coupling feature (illustratively, an internal threaded surface 144) that couples to an outlet coupling feature (illustratively, an external threaded surface 112) of the pressure generating actuator 104. The inlet portion 142 also includes an inlet 146 that receives pressurized fluid from the outlet 114 of the pressure generating actuator 104. The inlet portion 142 is coupled to a syringe chamber 148, and the syringe chamber 148 includes a syringe channel 150 that receives the pressurized fluid from the inlet portion 142. The syringe channel 150 carries a syringe piston 152, and when the syringe channel 150 receives the pressurized fluid, the syringe piston 152 translates away from the inlet portion 142 and toward the outlet portion 154 of the syringe assembly 140. Illustratively and as described in further detail below, the syringe piston 152 carries a magnetic member 156 that helps determine the position of the syringe piston 152 in the syringe channel 150. The syringe channel 150 also carries a therapeutic agent (illustratively, 2.25 mL of therapeutic agent, although other suitable volumes may be carried alternatively, including, for example, 2.08 mL, 1.08 mL, or 0.58 mL) between the syringe piston 152 and the outlet portion 154 (more specifically, the needle 18). Thus, translation of the syringe piston 152 in the syringe channel 150 causes the needle 18 to expel the therapeutic agent therefrom. In other embodiments, different arrangements are possible. For example, the inlet portion 142 and the syringe chamber 148 may be integrally formed with each other, or the syringe assembly 140 may be replaced by another type of therapeutic agent container, such as a bellows or sac structure.

[0082] Figure 22-23An electronic assembly 158 of the therapeutic agent delivery system 10 is illustrated. The electronic assembly 158 includes an electronic controller 160 that is operatively coupled to and receives power from a power source 162 (illustratively, a battery). The controller 160 is operatively coupled to a sleeve sensor 164 that determines whether the sleeve 24 has been translated relative to the housing 12 and the user input 22 is thereby "unlocked" (illustratively, two electrical contacts 166 that engage the sleeve 24 and thereby close an electrical circuit when the sleeve 24 is translated relative to the housing 12). The controller 160 is operatively coupled to an indicator device 168 (comprising, for example, a visual and / or audible indicator) that indicates a status of the system 10 (e.g., the sleeve 24 has been translated relative to the housing 12 and the user input 22 is thereby unlocked). The controller 160 is operatively coupled to a user input sensor 169 (illustratively, an electrical switch 170) that determines whether the user input 22 has been actuated. If the user input 22 has been actuated, the indicator device 210 may provide an indication (e.g., a visual and / or audible indication). The controller 160 is operatively coupled to a piston sensor 172 that is configured to determine the position of the syringe piston 152 in the syringe chamber 148 (e.g., to determine whether the syringe piston 152 has moved toward the syringe outlet portion 154, thereby indicating that the therapeutic agent has been expelled from the needle 18). Illustratively, the piston sensor 172 is a Hall effect sensor 174 that is configured to sense the magnetic member 156 carried by the syringe piston 152. In other embodiments, the piston sensor 172 may be an optical sensor. If the magnetic member 156 and the syringe piston 152 have moved toward the syringe outlet portion 154, the indicator device 210 may provide an indication (e.g., a visual and / or audible indication).

[0083] Illustratively, actuation of the therapeutic agent delivery system 10 is as follows. Fig.24 As shown in FIG. 1 , the end cap 176 and the needle cover 178 are removed from the distal portion 26 of the therapeutic agent delivery system 10 . Figure 25-28 The therapeutic agent delivery system 10 is illustrated in a first configuration (which may also be referred to as a "locked" configuration). In the first configuration, the sleeve 24 is disposed in an exposed configuration (i.e., the sleeve 24 partially extends from the distal housing portion 28) and is compressed between the sleeve 24 and the proximal housing portion 38 (see FIG. Fig. 27 and 28 ) of the extension spring 180 urges the sleeve 24 to remain in the exposed configuration. In the first configuration and as Fig.25 As specifically shown in FIG. 1 , the cam 116 of the pressure generating actuator 104 is disposed in the proximal slot portion 66 of the sleeve 24. In the first configuration and as shown in FIG. Fig.26As specifically shown in FIG. 1 , the input member constraint 92 is disposed in a first rotational configuration relative to the user input member 22 and the housing 12. In the first rotational configuration, the input member constraint 92 resists actuation of the user input member 22 due to contact between the constraint surface 98 of the input member constraint 92 and the constraint surface 88 of the user input member 22. In the first configuration and as shown in FIG. Fig. 27 As specifically shown in FIG. 1 , the therapeutic agent delivery assembly 16 is disposed in a stowed configuration (illustratively, a configuration in which the needle 18 is disposed entirely within the housing 12). Fig.28 As particularly shown in FIG. 1 , the sleeve 24 is disposed away from the electrical contacts 166 .

[0084] Figure 29-30 The therapeutic agent delivery system 10 is illustrated in a second configuration (which may also be referred to as an "unlocked" configuration). The therapeutic agent delivery system 10 moves from the first configuration to the second configuration when the sleeve 24 is pushed or pressed into a surface (e.g., the skin of a subject) and the sleeve 24 is translated relative to the housing 12 from the exposed configuration to the retracted configuration (illustratively, a configuration in which the sleeve 24 is fully disposed within the housing 12). Fig.29 and 30 As specifically shown in FIG. 1 , translation of the sleeve 24 from the exposed configuration to the retracted configuration produces relative movement of the cam 116 of the pressure generating actuator 104 and the slot 64 of the sleeve 24. More specifically, the cam 116 translates in the helically extending proximal portion 66 of the slot 64. This translation causes the pressure generating actuator 104, the expansion spring 182 compressed between the pressure generating actuator 104 and the input member restraint 92, and the input member restraint 92 to rotate relative to the housing 12 from a first rotational configuration to a second rotational configuration. In the second configuration and as shown in FIG. Fig.31 and 32 , the sleeve 24 engages the electrical contacts 166 and thereby closes the circuit. When the circuit is closed, the indicator device 168 can provide an indication (e.g., a visual and / or audible indication). In the second configuration, the therapeutic agent delivery system 10 can be returned to the first configuration by moving the therapeutic agent delivery system 10 away from the surface (more specifically, by allowing the extension spring 180 to expand and move the sleeve 24 to the exposed configuration).

[0085] Go to Figure 33-34, in the second configuration, the constraint surface 98 of the input constraint 92 is angularly misaligned with the constraint surface 88 of the user input 22, and the opening 96 of the input constraint 92 is angularly aligned with the constraint surface 88 of the user input 22. As a result, the user input 22 can be actuated (illustratively, by translating the user input 22 relative to the housing 12 in a direction substantially parallel to the longitudinal axis 14 (i.e., parallel ±5 degrees)), which causes the actuation surface 90 of the user input 22 to engage the actuation surface 100 of the input constraint 92. The user input 22 thereby rotates the input constraint 92 from the second rotational configuration to the third rotational configuration, as shown in FIG. Fig.34 As specifically shown, this causes the boss 102 of the input constraint 92 to slide over and disengage the boss 126 of the shuttle 122. The user input 22 may also actuate the switch 170, and the indicator device 168 may provide an indication (eg, a visual and / or audible indication).

[0086] like Fig.35 As shown in FIG. 1 , the deployment spring 182 is relatively unconstrained when the input member restraint 92 and the shuttle 122 are disengaged. As a result, the deployment spring 182 expands and pushes the therapeutic agent delivery assembly 16 distally relative to the housing 12. Fig.36 , the therapeutic agent delivery assembly 16 thereby moves from the stowed configuration to the deployed configuration (illustratively, a configuration in which the needle 18 is partially exposed at the distal end portion 26 of the housing 12 and is configured to engage with and deliver the therapeutic agent to the subject). Illustratively, the needle 18 translates from the stowed configuration to the deployed configuration in a direction substantially parallel to the longitudinal axis 14 (i.e., parallel ±5 degrees). Again referring to Fig.35 , the distal translation of the therapeutic agent delivery assembly 16 relative to the housing 12 also causes the radially outwardly extending fingers 132 of the shuttle 122 to engage and slide on the helically extending ramps 46 of the proximal housing portion 38. This engagement causes the shuttle 122 to rotate relative to the mixing chambers 106, 108 of the pressure generating actuator 104 (illustratively, about an axis substantially parallel to the longitudinal axis 14 (i.e., parallel ±5 degrees)), which actuates the pressure generating actuator 104. More specifically and as shown Fig.37 , rotation of the shuttle 122 relative to the first and second mixing chambers 106, 108 causes the radially inwardly extending projection 134 of the shuttle 122 to angularly misalign with the radially outwardly extending projection 138 of the mixing piston 120, and causes the groove 136 of the shuttle 122 to angularly align with the radially outwardly extending projection 138 of the mixing piston 120. As a result, the actuator spring 118 is relatively unconstrained, and as shown in FIG. Fig.38, the actuator spring 118 expands and translates the mixing piston 120 into the shuttle 122 and the first mixing chamber 106. The reagents in the first mixing chamber 106 and the second mixing chamber 108 then mix and react to provide the pressurized gas that the pressure generating actuator 104 delivers from the actuator outlet 114.

[0087] Now go to Fig.39 , the pressure generating actuator 104 delivers pressurized gas to the syringe channel 150, which causes the syringe piston 152 to translate distally within the syringe channel 150. As a result, the syringe piston 152 pushes the therapeutic agent distally to the needle 18, and the needle 18 expels the therapeutic fluid and delivers the therapeutic fluid to the subject. The piston sensor 172 can sense that the magnetic member 156 and the syringe piston 152 are disposed near the outlet portion 154 of the syringe assembly 140, and the indicator device 168 can provide an indication (e.g., a visual and / or audible indication).

[0088] After the therapeutic agent delivery system 10 discharges the therapeutic agent into the subject and as Figure 40-41 As shown, the user may cease pressing the therapeutic agent delivery system 10 against the surface. As a result, the extension spring 180 becomes relatively unrestrained and expands to translate the housing 12 and the therapeutic agent delivery assembly 16 proximally relative to the sleeve 24. The needle 18 is thereby disposed in a withdrawn configuration (illustratively, a configuration in which the needle 18 is fully disposed within the sleeve 24). Fig.41 , the radially inwardly extending projections 36 of the distal housing portion 28 engage and slide over the radially outwardly extending projections 58 of the sleeve 24 to prevent the housing 12 and therapeutic agent delivery assembly 16 from translating distally relative to the sleeve 24 (i.e., to "lock" the therapeutic agent delivery system 10). The therapeutic agent delivery system 10 may then be discarded.

[0089] Figure 42-47 A therapeutic agent delivery system 210 is illustrated according to another embodiment of the present disclosure. Illustratively, except as described below, the therapeutic agent delivery system 210 has the same structure as the therapeutic agent delivery system 10. The therapeutic agent delivery system 210 is moved from a first configuration to a second configuration (which may also be referred to as an "unlocked" configuration) by pressing the sleeve 212 into a surface (e.g., the skin of a subject) and translating the sleeve 212 proximally relative to the housing 214. The user input 218 may then be translated distally to actuate the device. More specifically and as described below Fig.43, the radially outwardly extending projection 216 of the user input member 218 engages and slides on the helically extending ramp 220 formed in the recess 222 of the actuator shuttle 224 of the pressure generating actuator 226. As a result, the actuator shuttle 224 rotates relative to the actuator mixing chamber 228 of the pressure generating actuator 226 and actuates the pressure generating actuator 226 in the same manner as the pressure generating actuator 104 described above. As shown in Figures 45-46 As shown in FIG. 1 , the pressure generating actuator 226 delivers pressurized gas to the inner channel 230 of the actuator coupling 232. The pressurized gas pushes the intermediate piston 234 and the syringe assembly 236 distally, and the needle 238 thereby moves from the stowed configuration to the deployed configuration. Fig.47 , after the needle 238 reaches the deployed configuration, the pressurized gas pushes the syringe piston 240 distally within the syringe chamber 242. The syringe chamber 242 carries the therapeutic agent opposite the pressure generating actuator 226, and the distal movement of the syringe piston 240 causes the syringe chamber 242 to deliver the therapeutic agent to the needle 238, and the needle 238 thereby expels the therapeutic agent. The needle 238 can then be moved to the withdrawn configuration, and the therapeutic agent delivery system 210 can then be locked in the same manner as the therapeutic agent delivery system 10 described above. The therapeutic agent delivery system 210 can then be discarded.

[0090] Although the present invention has been described as having an exemplary design, the present invention may be further modified within the spirit and scope of the present disclosure. Therefore, this application is intended to cover any variation, use or adjustment of the present invention using the underlying principles of the present invention. In addition, this application is intended to cover those deviations from the present disclosure as long as these are within the common knowledge or customary practice of the field to which the present invention belongs and fall within the limitations of the appended claims.

Claims

1. A therapeutic agent delivery system comprising: a housing having a distal portion; a therapeutic agent delivery assembly carried by the housing, the therapeutic agent delivery assembly comprising: a chamber including a passage; a therapeutic agent carried in the channel; a needle in communication with the channel; the therapeutic agent delivery assembly being translatable relative to the housing from a stowed configuration to a deployed configuration in which the needle at least partially extends distally from the distal end portion of the housing; a user input configured to be actuated by a user, actuation of the user input causing the therapeutic agent delivery assembly to translate from the stowed configuration to the deployed configuration; an input member restraint rotatable relative to the housing from a first rotational configuration in which the input member restraint prevents actuation of the user input member to a second rotational configuration in which the input member restraint permits actuation of the user input member; and a sleeve translatable relative to the housing from an exposed configuration to a retracted configuration in which the sleeve at least partially extends distally from the distal end of the housing and when translated from the exposed configuration to the retracted configuration, the sleeve rotates the input member constraint from the first rotational configuration to the second rotational configuration; wherein the therapeutic agent delivery assembly further comprises a pressure generating actuator; wherein actuation of the user input causes the pressure generating actuator to pressurize the therapeutic agent, deliver the therapeutic agent from the channel to the needle, and expel the therapeutic agent from the needle; wherein the pressure generating actuator comprises a mixing chamber and a shuttle carried by the mixing chamber, and when the shuttle rotates relative to the mixing chamber, the pressure generating actuator pressurizes the therapeutic agent.

2. The therapeutic agent delivery system of claim 1 , further comprising a cam and slot mechanism coupling the input member constraint to the sleeve, the cam and slot mechanism causing the input member constraint to rotate from the first rotational configuration to the second rotational configuration when the sleeve translates from the exposed configuration to the retracted configuration.

3. The therapeutic agent delivery system according to claim 2, wherein: The cam and slot mechanism includes a slot and a cam slidably received in the slot, the sleeve includes the slot, and the input member constraint is coupled to the cam.

4. The therapeutic agent delivery system according to any one of claims 1 to 3, wherein The housing defines a longitudinal axis, and the needle translates from the stowed configuration to the deployed configuration in a delivery direction substantially parallel to the longitudinal axis.

5. The therapeutic agent delivery system according to claim 4, wherein: The input member constraint rotates from the first rotational configuration to the second rotational configuration about a rotational axis substantially parallel to the longitudinal axis.

6. The therapeutic agent delivery system according to any one of claims 4 and 5, wherein The user input is configured to be actuated in an actuation direction substantially parallel to the longitudinal axis.

7. The therapeutic agent delivery system of any one of claims 1 to 6, further comprising a spring that urges the sleeve toward the exposed configuration.

8. The therapeutic agent delivery system according to any one of claims 1 to 7, wherein The housing also includes a proximal portion opposite the distal portion, and the user input extends proximally from the proximal portion of the housing.

9. A therapeutic agent delivery system comprising: a housing having a distal portion; a therapeutic agent delivery assembly carried by the housing, the therapeutic agent delivery assembly comprising: a chamber including a passage; a therapeutic agent carried in the channel; a needle in communication with the channel; a pressure generating actuator in communication with the passage, actuation of the pressure generating actuator causing the therapeutic agent to be delivered from the passage to the needle and causing the therapeutic agent to be expelled from the needle; the therapeutic agent delivery assembly being translatable relative to the housing from a stowed configuration to a deployed configuration in which the needle at least partially extends distally from the distal end portion of the housing; a user input configured to be actuated by a user, actuation of the user input causing actuation of the pressure generating actuator; an input member restraint rotatable relative to the housing from a first rotational configuration in which the input member restraint prevents actuation of the user input member to a second rotational configuration in which the input member restraint permits actuation of the user input member; and a sleeve translatable relative to the housing from an exposed configuration to a retracted configuration in which the sleeve at least partially extends distally from the distal end portion of the housing and when translated from the exposed configuration to the retracted configuration, the sleeve rotates the input member constraint from the first rotational configuration to the second rotational configuration; The pressure generating actuator includes a mixing chamber and a shuttle carried by the mixing chamber, and the pressure generating actuator is actuated when the shuttle rotates relative to the mixing chamber.

10. The therapeutic agent delivery system of claim 9, further comprising a cam and slot mechanism coupling the input member constraint to the sleeve, the cam and slot mechanism causing the input member constraint to rotate from the first rotational configuration to the second rotational configuration when the sleeve translates from the exposed configuration to the retracted configuration.

11. The therapeutic agent delivery system according to any one of claims 9 to 10, wherein: The housing defines a longitudinal axis, and the therapeutic agent delivery assembly translates from the stowed configuration to the deployed configuration in a delivery direction substantially parallel to the longitudinal axis.

12. A therapeutic agent delivery system comprising: a housing having a distal portion; a therapeutic agent delivery assembly carried by the housing, the therapeutic agent delivery assembly comprising: a chamber including a passage; a therapeutic agent carried in the channel; a needle in communication with the channel; a pressure generating actuator in communication with the passage, actuation of the pressure generating actuator delivering the therapeutic agent from the passage to the needle and causing the therapeutic agent to be expelled from the needle; the therapeutic agent delivery assembly being translatable relative to the housing from a stowed configuration to a deployed configuration in which the needle at least partially extends distally from the distal end portion of the housing; a user input configured to be actuated by a user, actuation of the user input translating the therapeutic agent delivery assembly from the stowed configuration to the deployed configuration and actuating the pressure generating actuator; an input restraint movable relative to the housing from a first configuration in which the input restraint prevents actuation of the user input to a second configuration in which the input restraint permits actuation of the user input; and a sleeve translatable relative to the housing from an exposed configuration to a retracted configuration in which the sleeve at least partially extends distally from the distal end portion of the housing and when translated from the exposed configuration to the retracted configuration, the sleeve causes the input member constraint to move from the first configuration to the second configuration; The pressure generating actuator includes a mixing chamber and a shuttle carried by the mixing chamber, and the pressure generating actuator is actuated when the shuttle rotates relative to the mixing chamber.

13. The therapeutic agent delivery system according to claim 12, wherein: The housing defines a longitudinal axis, and the therapeutic agent delivery assembly translates from the stowed configuration to the deployed configuration in a delivery direction substantially parallel to the longitudinal axis.

14. A therapeutic agent delivery system comprising: a housing having a proximal portion and a distal portion; a user input coupled to the proximal portion of the housing and configured to be actuated by a user; a sleeve coupled to the distal portion of the housing; a therapeutic agent delivery assembly carried by the housing, the therapeutic agent delivery assembly comprising: a chamber including a passage; a therapeutic agent carried in the channel; a needle in communication with the channel; and a pressure generating actuator in communication with the passage; The therapeutic agent delivery system has: a locked configuration wherein the sleeve at least partially extends distally from the distal end portion of the housing; an unlocked configuration in which the sleeve is forced into the distal portion of the housing; a deployed configuration wherein the needle at least partially extends distally from the distal end portion of the housing; and an actuation configuration wherein pressurized fluid from the pressure generating actuator causes the therapeutic agent to be delivered from the passageway to the needle and causes the therapeutic agent to be expelled from the needle; The pressure generating actuator includes a mixing chamber and a shuttle carried by the mixing chamber, and the pressure generating actuator is actuated when the shuttle rotates relative to the mixing chamber.

15. The therapeutic agent delivery system of claim 14, further comprising a rotatable input member constraint, wherein in the locked configuration, the input member constraint prevents actuation of the user input member, and in the unlocked configuration, the input member constraint allows actuation of the user input member.

16. The therapeutic agent delivery system according to any one of claims 14 and 15, further comprising: an extension spring urging the sleeve into the locked configuration; and A deployment spring urges the needle into the deployed configuration.

17. The therapeutic agent delivery system according to any one of claims 14 to 16, further comprising a drug.